Sökning: onr:"swepub:oai:DiVA.org:uu-393123" >
Real-world prevalen...
Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non small-cell lung cancer : The global, multicenter EXPRESS study
-
- Dietel, M. (författare)
- Univ Med Berlin, Charite, Inst Pathol, Berlin, Germany
-
- Savelov, N. (författare)
- Moscow City Oncol Hosp 62, Dept Pathol, Moscow, Russia
-
- Salanova, R. (författare)
- Hosp Gastroenterol Dr Carlos Bonorino Udaondo, Dept Pathol, Buenos Aires, DF, Argentina
-
visa fler...
-
- Micke, Patrick (författare)
- Uppsala universitet,Klinisk och experimentell patologi,Patrick Micke
-
- Bigras, G. (författare)
- Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
-
- Hida, T. (författare)
- Aichi Canc Ctr, Dept Thorac Oncol, Nagoya, Aichi, Japan
-
- Antunez, J. (författare)
- Univ Hosp Santiago Compostela, Pathol Dept, La Coruna, Spain
-
- Skov, B. Guldhammer (författare)
- Rigshosp, Dept Pathol, Copenhagen, Denmark
-
- Hutarew, G. (författare)
- Univ Hosp, Inst Pathol, Salzburg, Austria;Paracelsus Med Univ Salzburg, Salzburg, Austria
-
- Sua, L. F. (författare)
- Fdn Valle Lili, Clin Res Ctr, Dept Pathol & Lab Med, Cali, Colombia
-
- Akita, H. (författare)
- Hokkaido Univ, Fac Med, Dept Med Oncol, Sapporo, Hokkaido, Japan;Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan
-
- Chan, O. S. H. (författare)
- Pamela Youde Nethersole Eastern Hosp, Dept Clin Oncol, Chai Wan, Hong Kong, Peoples R China
-
- Piperdi, B. (författare)
- Merck & Co Inc, Kenilworth, NJ USA
-
- Burke, T. (författare)
- Merck & Co Inc, Ctr Observat & Real World Evidence, Kenilworth, NJ USA
-
- Khambata-Ford, S. (författare)
- Merck & Co Inc, Kenilworth, NJ USA
-
- Deitz, A. C. (författare)
- Merck & Co Inc, Ctr Observat & Real World Evidence, Kenilworth, NJ USA
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2019
- 2019
- Engelska.
-
Ingår i: Lung Cancer. - : Elsevier BV. - 0169-5002 .- 1872-8332. ; 134, s. 174-179
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- ObjectivesTumor programmed death ligand 1 (PD-L1) expression is associated with improved clinical benefit from immunotherapies targeting the PD-1 pathway. We conducted a global, multicenter, retrospective observational study to determine real-world prevalence of tumor PD-L1 expression in patients with NSCLC.Materials and methodsPatients ≥18 years with histologically confirmed stage IIIB/IV NSCLC and a tumor tissue block (≤5 years old) obtained before treatment were identified in 45 centers across 18 countries. Tumor samples from eligible patients were selected consecutively, when possible. PD-L1 expression was evaluated at each center using the PD-L1 IHC 22C3 pharmDx kit (Agilent, Santa Clara, CA, USA).ResultsOf 2617 patients who met inclusion criteria, 2368 (90%) had PD-L1 data; 530 (22%) patients had PD-L1 TPS ≥ 50%, 1232 (52%) had PD-L1 TPS ≥ 1%, and 1136 (48%) had PD-L1 TPS < 1%. The most common reason for not having PD-L1 data (n = 249) was insufficient tumor cells (<100) on the slide (n = 170 [6%]). Percentages of patients with PD-L1 TPS ≥ 50% and TPS ≥ 1%, respectively were: 22%/52% in Europe; 22%/53% in Asia Pacific; 21%/47% in the Americas, and 24%/55% in other countries. Prevalence of EGFR mutations (19%) and ALK alterations (3%) was consistent with prior reports from metastatic NSCLC studies. Among 1064 patients negative for both EGFR mutation and ALK alteration, the percentage with PD-L1 TPS ≥ 50% and TPS ≥ 1%, respectively, were 27% and 53%.ConclusionsThis is the largest real-world study in advanced NSCLC to date evaluating PD-L1 tumor expression using the 22C3 pharmDx kit. Testing failure rate was low with local evaluation of PD-L1 TPS across a large number of centers. Prevalence of PD-L1 TPS ≥ 50% and TPS ≥ 1% among patients with stage IIIB/IV NSCLC was similar across geographic regions and broadly consistent with central testing results from clinical trial screening populations.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Klinisk laboratoriemedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Clinical Laboratory Medicine (hsv//eng)
Nyckelord
- non-small-cell lung cancer
- PD-L1
- Biomarker
- Prevalence
- Patologi
- Pathology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Dietel, M.
-
Savelov, N.
-
Salanova, R.
-
Micke, Patrick
-
Bigras, G.
-
Hida, T.
-
visa fler...
-
Antunez, J.
-
Skov, B. Guldham ...
-
Hutarew, G.
-
Sua, L. F.
-
Akita, H.
-
Chan, O. S. H.
-
Piperdi, B.
-
Burke, T.
-
Khambata-Ford, S ...
-
Deitz, A. C.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Klinisk laborato ...
- Artiklar i publikationen
-
Lung Cancer
- Av lärosätet
-
Uppsala universitet